8-K: ImmuCell Reports Strong Preliminary Q2 2025 Sales Growth, Addresses Production Backlog

ImmuCell Corporation announced preliminary, unaudited product sales for the second quarter of 2025, showing significant growth across all reported periods and a substantial reduction in its order backlog.

Summary

• Preliminary, unaudited product sales for the three-month period ended June 30, 2025, increased by 18% to $6.4 million compared to $5.5 million in the same period of 2024.
• Sales for the six-month period ended June 30, 2025, increased by 14% to $14.5 million compared to $12.7 million in the same period of 2024.
• Sales for the nine-month period ended June 30, 2025, increased by 25% to $22.3 million compared to $17.8 million in the same period of 2024.
• Sales for the twelve-month period ended June 30, 2025, increased by 22% to $28.3 million compared to $23.2 million in the same period of 2024.
• The company has met current customer demand and reduced its order backlog to under $100,000 as of June 30, 2025, a significant decrease from approximately $3.4 million as of May 6, 2025.
• Production capacity has increased to over $30 million per year, allowing the company to ship within one week of order receipt.
• The company is initiating Investigational Product use of Re-Tain during the last six months of 2025 to test market acceptance and collect critical product performance data, though this initiative is not expected to generate significant revenue or profit.
• Approval of the Non-Administrative New Animal Drug Application (NADA) for Re-Tain is still critically constrained by clearing inspectional observations at the facilities of the company's contract manufacturer.

Sentiment

Score: 7

Explanation: The sentiment is largely positive due to strong sales growth, successful reduction of backlog, and increased production capacity. The company is actively pursuing new business and planning further expansion. However, the score is tempered by past production delays and the ongoing critical regulatory hurdle for Re-Tain's NADA approval, which is dependent on a third-party contract manufacturer's facility observations.

Positives

• Product sales increased significantly across all reported periods: 18% for the three-month period, 14% for the six-month period, 25% for the nine-month period, and 22% for the twelve-month period ended June 30, 2025.
• Current customer demand has been met, and the order backlog was reduced to under $100,000 as of June 30, 2025, a substantial decrease from approximately $3.4 million as of May 6, 2025.
• Production output has increased, allowing the company to ship within one week of order receipt.
• The commercial team has transitioned its focus from managing product allocations to pursuing new business and re-engaging customers affected during the period of short supply.
• The company is evaluating further investments to increase production capacity by an additional 33% to approximately $40 million or more to capitalize on potential demand growth.
• Initiating Investigational Product use of Re-Tain allows for market acceptance testing and collection of critical product performance data using available inventory before shelf-life expiration.

Negatives

• Investments to increase production capacity to over $30 million per year were challenging and took longer than planned.
• The Investigational Product use of Re-Tain is not expected to generate significant revenue or profit.
• Clearing inspectional observations at the contract manufacturer's facilities remains the critical path constraint to Non-Administrative New Animal Drug Application (NADA) approval for Re-Tain.

Risks

• Difficulties or delays in development, testing, regulatory approval, production, and marketing of products (including the First Defense product line and Re-Tain).
• Competition within anticipated product markets.
• Customer acceptance of new and existing products.
• Product performance issues.
• Alignment between manufacturing resources and product demand, including the consequences of backlogs.
• Uncertainty associated with the timing and volume of customer orders as the company comes out of a prolonged backlog.
• Adverse impacts of supply chain disruptions on operations and customer and supplier relationships.
• Commercial and operational risks relating to current and planned expansion of production capacity.
• Impacts of inflation and rising interest rates on operating expenses and financial results.
• Future incidence rates of subclinical mastitis and producers' level of interest in treating subclinical mastitis.
• Expected efficacy of new products.
• Estimates about the market size for products.
• Future market share of and revenue generated by current products and products still in development.
• Ability to increase production output and reduce costs of goods sold per unit.
• Adequacy of own manufacturing facilities or those of third parties to meet demand for products on a timely basis.
• Impacts of backlogs on customer relationships.
• Efficacy of contamination remediation efforts and whether future contamination events will occur.
• Anticipated costs of (or time to complete) planned expansions of manufacturing facilities and the adequacy of funds available for these projects.
• Robustness of manufacturing processes to meet future demand and related technical issues.
• Salability of products currently held in inventory pending regulatory approval.
• Future regulatory requirements relating to products.
• Future expense ratios and margins.
• Future consequences and effectiveness of investments in the business.
• Anticipated changes in manufacturing capabilities and efficiencies.
• Future effectiveness in competing against competitors within both existing and anticipated product markets.

Future Outlook

The company plans to continue providing prompt, preliminary sales reports. It is evaluating incremental investments to increase production capacity by an additional 33% to approximately $40 million or more to capitalize on potential demand growth in North American dairy and beef markets. The commercial team is now focused on pursuing new business and re-engaging customers after resolving supply shortages. The company is initiating Investigational Product use of Re-Tain during the last six months of 2025 to test market acceptance and collect performance data, though this is not expected to generate significant revenue or profit. The Non-Administrative New Animal Drug Application (NADA) approval for Re-Tain remains contingent on clearing inspectional observations at the contract manufacturer's facilities.

Management Comments

• "Our investments to increase production capacity to over $30 million per year were challenging and did take longer than we had planned." Michael F. Brigham, President and CEO of ImmuCell.
• "We are now evaluating incremental liquid processing and freeze-drying investments to increase capacity by an additional 33% to approximately $40 million or more to capitalize on potential demand growth in the North American dairy and beef markets." Michael F. Brigham, President and CEO of ImmuCell.
• "Although buffer stock replenishment and backlog depletion may result in one-time lifts in volume, our teams remain focused on the sustainable, long-term growth of the First Defense product line." Michael F. Brigham, President and CEO of ImmuCell.
• "This exciting initiative reflects the innovative nature of this novel product and its safety profile and allows us to utilize available inventory before shelf-life expiration to collect critical product performance data." (referring to Re-Tain Investigational Product use) Michael F. Brigham, President and CEO of ImmuCell.

Industry Context

ImmuCell operates in the animal health sector, specifically focusing on products for dairy and beef cattle. Its flagship product, First Defense, provides immediate immunity to newborn calves. The company is also developing Re-Tain, a novel treatment for subclinical mastitis in dairy cows, which aims to offer an alternative to traditional antibiotics by avoiding FDA-required milk discard or pre-slaughter withdrawal restrictions. This positions Re-Tain as a potentially significant product in the dairy industry, addressing a common health issue with a more convenient solution. The focus on increasing production capacity reflects growing demand in the North American dairy and beef markets.

Stakeholder Impact

• Shareholders: Positive impact from strong sales growth and reduced backlog, indicating improved operational efficiency and potential for future revenue. However, ongoing regulatory delays for Re-Tain and past production challenges introduce some uncertainty.
• Customers: Positive impact as product supply now meets demand, backlog is cleared, and shipments are prompt, leading to improved customer satisfaction and re-engagement efforts.
• Employees: Shift in focus for the commercial team from managing allocations to new business development, potentially leading to new opportunities and stability.
• Suppliers: Continued demand for raw materials and components due to increased production and planned capacity expansion.

Next Steps

• Continue providing prompt, preliminary reports on product sales.
• Evaluate incremental liquid processing and freeze-drying investments to increase capacity by an additional 33% to approximately $40 million or more.
• Commercial team to focus on pursuing new business and re-engaging customers.
• Initiate Investigational Product use of Re-Tain during the last six months of 2025 to test market acceptance and collect critical product performance data.
• Await Non-Administrative New Animal Drug Application (NADA) approval for Re-Tain, contingent on clearing inspectional observations at the contract manufacturer's facilities.
• Host a conference call on August 15, 2025, to discuss unaudited financial results for Q2 2025.
• Make an updated Corporate Presentation slide deck available after market closes on August 14, 2025.

Key Dates

Keywords

ImmuCell Corporation, ICCC, Animal Health, Dairy Cattle, Beef Cattle, First Defense, Re-Tain, Preliminary Sales, Q2 2025, Sales Growth, Order Backlog, Production Capacity, Subclinical Mastitis, FDA Approval, NADA, SEC Filing, 8-K, Financial Results